ReviewDiagnostics (Basel, Switzerland)2022
Clinical Management of Herpes Simplex Virus Keratitis.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Global research trend of Herpes simplex keratitis: a bibliometric analysis and visualization from 1941 to 2024.Frontiers in medicine · 2025Pooled it
- A novel corneal epithelial cell culture assay for assessing topical antivirals against herpes simplex virus keratitis.Biochemistry and biophysics reports · 2026Article
- Exosome-Associated Gene Network and the Role of SPP1 in Herpes Stromal Keratitis and the Therapeutic Modulation by Ursolic Acid.Investigative ophthalmology & visual science · 2026Article
- Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Review
- Viral eye: Emerging insights into corneal and ocular surface viral infections.World journal of virology · 2025Review
- Correlation analysis of the copy number of aqueous humor HSV DNA with anterior chamber reaction, topical steroid responsiveness and prognosis of endothelial herpes simplex keratitis.BMC ophthalmology · 2025Article
- Herpetic Eye Disease During the COVID-19 Pandemic at an Urban Hospital System.Ocular immunology and inflammation · 2025Article
- Article
- Hexokinase-2 as a Therapeutic Target: Alleviating Herpes Simplex Keratitis Through Metabolic Reprogramming.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- An exploration of the ocular mysteries linking nanoparticles to the patho-therapeutic effects against keratitis.Journal of nanobiotechnology · 2025Review
- Antimicrobial Activity of Probiotic Bacteria Isolated from Plants: A Review.Foods (Basel, Switzerland) · 2025Review
- Tear metabolomics reveals novel potential biomarkers in epithelial herpes simplex keratitis.BMC ophthalmology · 2025Article
- Luteolin alleviates Herpes Simplex Keratitis by inhibiting inflammatory responses via suppressing the PTGS2/NF-κB signaling pathway.American journal of translational research · 2025Article
- Herpes Simplex Keratitis Following Corneal Crosslinking for Keratoconus: A One-Year Case Series Follow-Up.Diagnostics (Basel, Switzerland) · 2024Article
- CRISPR-Cas9-mediated genome editing delivered by a single AAV9 vector inhibits HSV-1 reactivation in a latent rabbit keratitis model.Molecular therapy. Methods & clinical development · 2024Article
- Immunological Considerations for the Development of an Effective Herpes Vaccine.Microorganisms · 2024Review
- Clinical and Demographic Characteristics of Herpetic Keratitis Patients-Tertiary Centre Experience.Medicina (Kaunas, Lithuania) · 2024Article
- Herpes simplex keratitis: A brief clinical overview.World journal of virology · 2024Review
- Exploring Heparanase Levels in Tears: Insights From Herpes Simplex Virus-1 Keratitis Patients and Animal Studies.Investigative ophthalmology & visual science · 2024Article
- Bilateral meibomian gland morphological alterations in unilateral herpes simplex keratitis based on artificial intelligence analysis.International journal of ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus (HSV) keratitis is one of the leading causes of blindness worldwide. Additionally, up to 90% of the population in some countries is seropositive for HSV. HSV can cause a wide spectrum of ocular disease ranging from blepharitis to retinitis. Although the initial clinical expressions of HSV-1 and HSV-2 are similar, HSV-2 has been reported more frequently in association with recurrent HSV disease. Besides irreversible vision loss from keratitis, HSV also causes encephalitis and genital forms of the disease. Despite these statistics, there remains no vaccine against HSV. Current treatment therapies for related ocular diseases include the use of oral and topical antivirals and topical corticosteroids. While effective in many cases, they fail to address the latency and elimination of the virus, making it ineffective in addressing recurrences, a factor which increases the risk of vision loss. As such, there is a need for continued research of other potential therapeutic targets. This review utilized several published articles regarding the manifestations of HSV keratitis, antiviral immune responses to HSV infection, and clinical management of HSV keratitis. This review will summarize the current knowledge on the host-virus interaction in HSV infections, as well as highlighting the current and potential antiviral therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.